ReproCell Inc
TSE:4978
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Guangdong Nedfon Air System Co Ltd
SZSE:301043
|
CN |
|
W
|
Welspun India Ltd
NSE:WELSPUNIND
|
IN |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
|
G
|
Guangdong Yuehai Feeds Group Co Ltd
SZSE:001313
|
CN |
|
Glory Flame Holdings Ltd
HKEX:8059
|
HK |
|
S
|
Stella International Holdings Ltd
HKEX:1836
|
HK |
|
L
|
Lendingtree Inc
LSE:0JTZ
|
US |
|
Yantai China Pet Foods Co Ltd
SZSE:002891
|
CN |
ReproCell Inc
Research & Development
ReproCell Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ReproCell Inc
TSE:4978
|
Research & Development
-¥636.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
SanBio Co Ltd
TSE:4592
|
Research & Development
-¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-¥3.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
PeptiDream Inc
TSE:4587
|
Research & Development
-¥4.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Research & Development
-¥6.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Research & Development
-¥1.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
ReproCell Inc
Glance View
ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
See Also
What is ReproCell Inc's Research & Development?
Research & Development
-636.7m
JPY
Based on the financial report for Dec 31, 2025, ReproCell Inc's Research & Development amounts to -636.7m JPY.
What is ReproCell Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-7%
Over the last year, the Research & Development growth was -31%. The average annual Research & Development growth rates for ReproCell Inc have been -11% over the past three years , and -7% over the past ten years .
